Fingerpaint Group is back on the hunt, scooping up strategic market access marketing firm The MYND Group in its latest acquisition.

Announced earlier this week, The Mynd Group deal is meant to bolster the agency’s market access offering, according to Bill McEllen, global president of Fingerpaint Group. 

It’s the 2022 MM+M Agency 100 honoree’s second acquisition of late to focus on market access — in 2020, the company picked up private equity firm Knox Lane.

“The Mynd Group brings extensive market access strategy, research, and launch experience across multiple categories, including in the growing vaccine category,” McEllen said in a statement. “This is our second market access acquisition in the last three years and is part of our continued commitment to evolving our market access capabilities to match the expectations and needs of the industry.”

Fingerpaint will be adding the Mynd Group to its specialty services offerings, spanning medical and scientific communications, market access, as well as branding capabilities.

“The Mynd Group takes a comprehensive and integrated marketing approach to solving some of the most pressing market access challenges faced by biopharma companies during their commercialization journey,” Brannon Cashion, president of specialty services at Fingerpaint, said in a statement. “Their extensive customer and channel (market access) experience drives innovative managed markets solutions.

Jonathan Magid, who currently serves as GM and EVP of The MYND Group, will continue on as managing director and report to Cashion.

Fingerpaint has been on an acquisition spree as of late, most recently snapping up PharmaHEALTHLabs, a healthcare communications agency with a focus on oncology and biologics. The agency will also be added under Fingerpaint’s specialty services offerings and rebranded as Fingerpaint Medical Communications.

That acquisition was Fingerpaint’s third one in the medical communications sphere in the last two years. Last year, the company acquired Parsons Medical Communications, which focuses on the eye care industry.

In a previous interview with MM+M, McEllen noted the company’s M&A strategy was to add best-in-class capabilities “anywhere there’s a real client need and where we feel we can do right by patients.”

“We’re bringing clients what they’re asking for, and we’re doing it with a group of companies that’s really answering the call for how they really want those services,” Mcellen continued.

The strategy has paid off well for Fingerpaint, too, with the top line growing from $85 million in 2020 to $135 million in 2021, according to MM+M’s Agency 100 revenue table.